Myeloma Trial, Recruiting (NCT06541860)

Myeloma Trial, Recruiting NCT06541860 Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia Condition: Myeloma

Printed from Voxsanity (voxsanity.com.au) — NCT06541860 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Myeloma

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Phase I:

People who have multiple myeloma that has come back or stopped responding to treatment, specifically after having been treated with a combination of anti-CD38 antibody therapy and a type of drug called an immunomodulatory drug (IMiD), and who have since started on a specific treatment combination called PVD
People aged 18 years or older
People who are able to understand and willingly sign a consent form agreeing to allow their medical data to be reviewed

Phase II:

People who have multiple myeloma that has come back or stopped responding to treatment after their first course of treatment, which included an anti-CD38 antibody therapy and an immunomodulatory drug (IMiD), and who have since started on an approved, standard treatment plan
People aged 18 years or older
People who are able to understand and willingly sign a consent form agreeing to allow their medical data to be reviewed

Who may not be able to join:

People who are not willing to give consent for their medical data to be reviewed

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06541860

Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia

Phase: Not Applicable

Status: Recruiting

Condition: Myeloma

More information: https://clinicaltrials.gov/study/NCT06541860

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Phase I:

People who have multiple myeloma that has come back or stopped responding to treatment, specifically after having been treated with a combination of anti-CD38 antibody therapy and a type of drug called an immunomodulatory drug (IMiD), and who have since started on a specific treatment combination called PVD
People aged 18 years or older
People who are able to understand and willingly sign a consent form agreeing to allow their medical data to be reviewed

Phase II:

People who have multiple myeloma that has come back or stopped responding to treatment after their first course of treatment, which included an anti-CD38 antibody therapy and an immunomodulatory drug (IMiD), and who have since started on an approved, standard treatment plan
People aged 18 years or older
People who are able to understand and willingly sign a consent form agreeing to allow their medical data to be reviewed

Who may not be able to join:

People who are not willing to give consent for their medical data to be reviewed

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Fondazione IRCCS Policlinico San Matteo di Pavia

Registry

ClinicalTrials.gov

Start date

21 August 2023

Est. completion

21 February 2028

Where this trial is recruiting

🇮🇹 Italy

Primary endpoints

To explore the efficacy and tolerability of different combinations, particularly the PVD regimen, in the emerging context of RRMM after anti-CD38 MoAb plus IMIDS therapy.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov